US6582703B2ExpiredUtilityA1
Isolated nucleotide sequences associated with multiple sclerosis or rheumatoid arthritis and a process of detecting
Est. expiryNov 26, 2016(expired)· nominal 20-yr term from priority
Inventors:Herve PerronFrederic BesemeFrederic BedinGlaucia Paranhos-BaccalaFlorence Komurian-PradelColette Jolivet-ReynaudBernard Mandrand
A61P 31/14C12N 2740/10051A61K 38/00C12N 9/1241C12N 2740/10022C12Q 1/702C12N 7/00C07K 14/005
61
PatentIndex Score
12
Cited by
183
References
5
Claims
Abstract
The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.
Claims
exact text as granted — not AI-modifiedWe claim:
1. An isolated or purified nucleic acid selected from a group consisting of SEQ ID NO: 87 or its complementary sequence.
2. An isolated or purified nucleic acid selected from a group consisting of SEQ ID NO: 88 or its complementary sequence.
3. An isolated or purified nucleic acid coding for a peptide sequence encoded by SEQ ID NO: 87, SEQ ID NO: 88, or their complementary sequences.
4. A process for detecting, in a biological sample, a virus associated with multiple sclerosis or rheumatoid arthritis, comprising:
contacting a probe to said biological sample under stringent conditions at which said probe hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NO: 87, SEQ ID NO: 88 and their complementary sequences; and
determining whether the probe hybridizes with nucleic material in the biological sample, wherein hybridization indicates the presence of said virus.
5. The process of claim 4 , wherein said probe comprises:
(a) a sequence of at least 10 contiguous monomers of a nucleotide sequence selected from the group consisting of SEQ ID NO: 87, SEQ ID NO: 88 and their complementary sequences.Join the waitlist — get patent alerts
Track US6582703B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.